At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 1,077 enrolled
Drug / intervention
FluMistdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Self-Administered Nasal Influenza Vaccine: Immunogenicity and Feasibility of Group Administration
Henry M. Jackson Foundation for the Advancement of Military Medicine·interventional·Posted Aug 30, 2013·Updated Feb 15, 2023
In Brief
A Phase 4 clinical trial evaluating FluMist for Influenza. Completed, enrolled 1,077 participants across 2 sites.
Detailed Summary
The purpose of this prospective, open-label clinical trial is to evaluate the immunogenicity of self-administered (SA) live, attenuated influenza vaccine (LAIV) in comparison with healthcare worker administered (HCWA) LAIV and to evaluate the feasibility of group self-administration of LAIV.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2012
First PostedAug 2013
Primary CompletionOct 2013
TodayJul 2026
First PostedAug 30, 2013
Enrollment StartSep 1, 2012
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 12.8 years ago
Interventions
FluMistdrug
FluMist Intranasal Vaccine